Dennis Mulroy Biography and Net Worth

CFO of AnaptysBio

Prior to Anaptys, Dennis served as chief financial officer of La Jolla Pharmaceutical Company, Taxus Cardium Pharmaceuticals Group, Molecular Imaging and SeraCare Life Sciences. He began his career as a Certified Public Accountant with Ernst & Young LLP after receiving his BBA degree in Accounting from the University of San Diego.

What is Dennis Mulroy's net worth?: The estimated net worth of Dennis Mulroy is at least $205.42 thousand as of September 16th, 2024. Mr. Mulroy owns 4,744 shares of AnaptysBio stock worth more than $205,415 as of December 5th. This net worth estimate does not reflect any other assets that Mr. Mulroy may own. Additionally, Mr. Mulroy receives a salary of $448,810.00 as CFO at AnaptysBio. Learn More about Dennis Mulroy's net worth.
How old is Dennis Mulroy?: Mr. Mulroy is currently 69 years old. There are 5 older executives and no younger executives at AnaptysBio. Learn More on Dennis Mulroy's age.
What is Dennis Mulroy's salary?: As the CFO of AnaptysBio, Inc., Mr. Mulroy earns $448,810.00 per year. There are 3 executives that earn more than Mr. Mulroy. The highest earning executive at AnaptysBio is Mr. Daniel R. Faga, President, CEO & Director, who commands a salary of $867,120.00 per year. Learn More on Dennis Mulroy's salary.
How do I contact Dennis Mulroy?: The corporate mailing address for Mr. Mulroy and other AnaptysBio executives is 10421 PACIFIC CENTER COURT SUITE 200, SAN DIEGO CA, 92121. AnaptysBio can also be reached via phone at (858) 362-6295 and via email at [email protected]. Learn More on Dennis Mulroy's contact information.
Has Dennis Mulroy been buying or selling shares of AnaptysBio?: Dennis Mulroy has not been actively trading shares of AnaptysBio over the course of the past ninety days. Most recently, Dennis Mulroy sold 12,220 shares of the business's stock in a transaction on Monday, September 16th. The shares were sold at an average price of $39.91, for a transaction totalling $487,700.20. Following the completion of the sale, the chief financial officer now directly owns 4,744 shares of the company's stock, valued at $189,333.04. Learn More on Dennis Mulroy's trading history.
Who are AnaptysBio's active insiders?: AnaptysBio's insider roster includes Daniel Faga (President & CEO), Dennis Fenton (Director), Paul Lizzul (Chief Medical Officer), Eric Loumeau (COO), Dennis Mulroy (CFO), Hollings Renton (Director), and Hamza Suria (CEO). Learn More on AnaptysBio's active insiders.
Are insiders buying or selling shares of AnaptysBio?: In the last twelve months, AnaptysBio insiders bought shares 2 times. They purchased a total of 71,830 shares worth more than $928,242.98. In the last twelve months, insiders at the biotechnology company sold shares 1 times. They sold a total of 20,925 shares worth more than $493,202.25. The most recent insider tranaction occured on July, 2nd when Director Hollings Renton sold 20,925 shares worth more than $493,202.25. Insiders at AnaptysBio own 33.5% of the company. Learn More about insider trades at AnaptysBio.
Information on this page was last updated on 7/2/2025.

Dennis Mulroy Insider Trading History at AnaptysBio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/16/2024	Sell	12,220	$39.91	$487,700.20	4,744
5/22/2024	Sell	1,500	$23.72	$35,580.00	964
1/30/2024	Sell	3,065	$23.63	$72,425.95	964
1/8/2024	Sell	2,180	$21.81	$47,545.80	4,029

Dennis Mulroy Buying and Selling Activity at AnaptysBio

AnaptysBio Company Overview

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Today's Range

Now: $43.30

$42.63

$45.32

50 Day Range

MA: $35.31

$23.27

$43.76

2 Week Range

Now: $43.30

$12.21

$45.32

Volume

591,640 shs

Average Volume

743,185 shs

Market Capitalization

$1.20 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.29

Dennis Mulroy Biography and Net Worth

What is Dennis Mulroy's net worth?

How old is Dennis Mulroy?

What is Dennis Mulroy's salary?

How do I contact Dennis Mulroy?

Has Dennis Mulroy been buying or selling shares of AnaptysBio?

Who are AnaptysBio's active insiders?

Are insiders buying or selling shares of AnaptysBio?